维普中文期刊产品整合服务
507篇 您的检索式:作者名="YAO Sheng"
    题名 作者 年代 出处 被引量
1Mapping wetland changes in China between 1978 and 2008显示文摘Four wetland maps for all China have been produced,based on Landsat and CBERS-02B remote sensing data between 1978 and 2008 (1978,1990,2000 and 2008).These maps were mainly developed by manual interpretation and validated by substantial field investigation in 2009.Based on these maps,we analyzed the 2008 wetland distribution in China and discussed wetland changes and their drivers over the past 30 years.(i) There were about 324097 km 2 of wetlands in 2008,for which inland marshes or swamps were the most common wetland type (35%),with lakes (26%) second.Most of the wetlands were in Heilongjiang,Inner Mongolia,Qinghai and Tibet,occupying about 55% of the national wetland area.(ii) From 1978 to 2008,China's wetland area continually and significantly decreased,by about 33% based on changes in the wetland map.This was in sharp contrast to the increase in artificial wetlands,which increased by about 122%.Inland marshes accounted for the main loss of total wetlands from 1978 to 2000.From 2000 through 2008,riverine and lacustrine wetlands constituted the main wetland loss.Fortunately however,the rate of wetland loss decreased from 5523 to 831 km 2 /a.(iii) The change ratio of lost natural wetlands (including inland and coastal wetlands) to non-wetlands has decreased slightly over the past 30 years.From 1978 to 1990,nearly all natural wetlands (98%) lost were transformed into non-wetlands.However,the ratio declined to 86% from 1990 to 2000,and to 77% from 2000 to 2008.(iv) All Chinese provinces were divided into three groups according to patterns of wetland changes,which could relate to the driving forces of such changes.Tibet was completely different from other provinces,as it was one representative example in which there was a net wetland increase,because of global warming and decreased human activity since 1990.Increased economic development caused considerable wetland loss in most eastern provinces,and artificial wetlands increased.NIU ZhenGuo ZHANG HaiYing WANG XianWei YAO WenBo ZHOU DeMin ZHAO KuiYi ZHAO Hui LI NaNa HUANG HuaBing LI CongCong YANG Jun LIU CaiXia LIU Shuang WANG Lin LI Zhan YANG ZhenZhong QIAO Fei ZHENG YaoMin CHEN YanLei SHENG YongWei GAO XiaoHong ZHU WeiHong WANG WenQing WANG Hong WENG YongLing ZHUANG DaFang LIU JiYuan LUO ZhiCai CHENG Xiao GUO ZiQi GONG Peng 2012Chinese Science Bulletin2012,57,22:51
2Growth-Defense Tradeoffs in Plants: A Balancing Act to Optimize Fitness显示文摘Bethany Huot Jian Yao Beronda L. Montgomery' Sheng Yang He 2014Molecular Plant2014,7,8:37
3The First Imported Case of Monkeypox in the Mainland of China—Chongqing Municipality,China,September 16,2022显示文摘Monkeypox is a zoonotic viral disease caused by the monkeypox virus(MPXV),and historically,all outbreaks have been linked to Africa;however,monkeypox has been posing an alarming challenge to the world in 2022(1)as approximately 60,000 cases have been reported in more than 100 nations and regions worldwide(2).Currently,many cases of monkeypox were identified in many nonendemic countries outside of Central and West Africa,and human-to-human transmission has occurred frequently,especially among men who have sex with men(MSM)presenting new clinical symptoms similar to syphilis and other sexually transmitted infections(3).Hua Zhao Wenling Wang Li Zhao Sheng Ye Jingdong Song Roujian Lu Hua Zong Changcheng Wu Wei Huang Baoying Huang Yao Deng Ruhan A Wujuan Xie Li Qi Wenbo Xu Hua Ling Wenjie Tan 2022China CDC weekly2022,4,38:35
4Anti-SARS-CoV-2 activities in vitro of Shuanghuanglian preparations and bioactive ingredients显示文摘Human infection with severe acute respiratory syndrome coronavirus 2(SARS-CoV-2)causes coronavirus disease 2019(COVID-19)and there is no cure currently.The 3CL protease(3CLpro)is a highly conserved protease which is indispensable for CoVs replication,and is a promising target for development of broad-spectrum antiviral drugs.In this study we investigated the anti-SARS-CoV-2 potential of Shuanghuanglian preparation,a Chinese traditional patent medicine with a long history for treating respiratory tract infection in China.We showed that either the oral liquid of Shuanghuanglian,the lyophilized powder of Shuanghuanglian for injection or their bioactive components dose-dependently inhibited SARS-CoV-23CLpro as well as the replication of SARS-CoV-2 in Vero E6 cells.Baicalin and baicalein,two ingredients of Shuanghuanglian,were characterized as the first noncovalent,nonpeptidomimetic inhibitors of SARS-CoV-23CLpro and exhibited potent antiviral activities in a cell-based system.Remarkably,the binding mode of baicalein with SARS-CoV-23CLpro determined by X-ray protein crystallography was distinctly different from those of known 3CLpro inhibitors.Baicalein was productively ensconced in the core of the substrate-binding pocket by interacting with two catalytic residues,the crucial S1/S2 subsites and the oxyanion loop,acting as a“shield”in front of the catalytic dyad to effectively prevent substrate access to the catalytic dyad within the active site.Overall,this study provides an example for exploring the in vitro potency of Chinese traditional patent medicines and effectively identifying bioactive ingredients toward a specific target,and gains evidence supporting the in vivo studies of Shuanghuanglian oral liquid as well as two natural products for COVID-19 treatment.Hai-xia Su Sheng Yao Wen-feng Zhao Min-jun Li Jia Liu Wei-juan Shang Hang Xie Chang-qiang Ke Hang-chen Hu Mei-na Gao Kun-qian Yu Hong Liu Jing-shan Shen Wei Tang Lei-ke Zhang Geng-fu Xiao Li Ni Dao-wen Wang Jian-ping Zuo Hua-liang Jiang Fang Bai Yan Wu Yang Ye Ye-chun Xu 2020Acta Pharmacologica Sinica2020,41,9:32
5Effects of glycyrrhetinic acid on collagen metabolism of hepatic stellate cells at different stages of liver fibrosis in rats显示文摘INTRODUCTIONLiver fibrosis is a dynamic course leading tocirrhosis from a various chronic liver diseases. Thepathological basis of fibrosis is the disturbance ofproduction and degradation of the extracellularmatrix (ECM), which causes accumulation of ECMin the liver[1,2].Ji Yao Wang Qi Sheng Zhang Ji Sheng Guo Mei Yu Hu Department of Gastroenterology, Zhongshan Hospital, Medical Center, Fu Dan University Shanghai Medical University), Shanghai 200032, China 2001World Journal of Gastroenterology2001,7,1:29
6Genetic correction of p-thalassemia patient-specific iPS cells and its use in improving hemoglobin production in irradiated SCID mice显示文摘Yixuan Wang Chen-Guang Zheng Yonghua Jiang Jiqin Zhang Jiayu Chen Chao Yao Qingguo Zhao Sheng Liu Ke Chen Juan Du Ze Yang Shaorong Gao 2012Cell Research2012,22,4:27
7Sliding mode control based guidance law with impact angle constraint显示文摘The terminal guidance problem for an unpowered lifting reentry vehicle against a stationary target is considered. In addition to attacking the target with high accuracy,the vehicle is also expected to achieve a desired impact angle. In this paper,a sliding mode control(SMC)-based guidance law is developed to satisfy the terminal angle constraint. Firstly,a specific sliding mode function is designed,and the terminal requirements can be achieved by enforcing both the sliding mode function and its derivative to zero at the end of the flight. Then,a backstepping approach is used to ensure the finite-time reaching phase of the sliding mode and the analytic expression of the control effort can be obtained. The trajectories generated by this method only depend on the initial and terminal conditions of the terminal phase and the instantaneous states of the vehicle.In order to test the performance of the proposed guidance law in practical application,numerical simulations are carried out by taking all the aerodynamic parameters into consideration. The effectiveness of the proposed guidance law is verified by the simulation results in various scenarios.Zhao Yao Sheng Yongzhi Liu Xiangdong 2014Chinese Journal of Aeronautics2014,27,1:22
8Obesity-related glomerulopathy: pathogenesis, pathologic, clinical characteristics and treatment显示文摘Tianhua Xu Zitong Sheng Li Yao 2017Frontiers of Medicine2017,11,3:23
9Clinical trial with traditional Chinese medicine intervention ''tonifying the kidney to promote liver regeneration and repair by affecting stem cells and their microenvironment'' for chronic hepatitis B-associated liver failure显示文摘AIM:To study the clinical efficacy of traditional Chinese medicine(TCM)intervention'tonifying the kidney to promote liver regeneration and repair by affecting stem cells and their microenvironment'('TTK')for treating liver failure due to chronic hepatitis B.METHODS:We designed the study as a randomized controlled clinical trial.Registration number of Chinese Clinical Trial Registry is Chi CTR-TRC-12002961.A total of 144 patients with liver failure due to infection with chronic hepatitis B virus were enrolled in this randomized controlled clinical study.Participants were randomly assigned to the following three groups:(1)a modern medicine control group(MMC group,36patients);(2)a'tonifying qi and detoxification'('TQD')group(72 patients);and(3)a'tonifying the kidney to promote liver regeneration and repair by affecting stem cells and their microenvironment'('TTK')group(36patients).Patients in the MMC group received general internal medicine treatment;patients in the'TQD'group were given a TCM formula'tonifying qi and detoxification'and general internal medicine treatment;patients in the'TTK'group were given a TCM formula of'TTK'and general internal medicine treatment.All participants were treated for 8 wk and then followed at 48 wk following their final treatment.The primaryefficacy end point was the patient fatality rate in each group.Measurements of various virological and biochemical indicators served as secondary endpoints.The one-way analysis of variance and the t-test were used to compare patient outcomes in the different treatment groups.RESULTS:At the 48-wk post-treatment time point,the patient fatality rates in the MMC,'TQD',and'TTK'groups were 51.61%,35.38%,and 16.67%,respectively,and the differences between groups were statistically significant(P<0.05).However,there were no significant differences in the levels of hepatitis B virus DNA or prothrombin activity among the three groups(P>0.05).Patients in the'TTK'group had significantly higher levels of serum total bilirubin compared to MMC subjects(339.40μmol/L±270.09μmol/L vs 176.13μmol/L±185.70μmol/L,P=0.014).Serum albumin levels were significantly increased in both the'TQD'group and'TTK'group as compared with the MMC group(31.30 g/L±4.77g/L,30.72 g/L±2.89 g/L vs 28.57 g/L±4.56 g/L,P<0.05).There were no significant differences in levels of alanine transaminase among the three groups(P>0.05).Safety data showed that there was one case of stomachache in the'TQD'group and one case of gastrointestinal side effect in the'TTK'group.CONCLUSION:Treatment with'TTK'improved the survival rates of patients with liver failure due to chronic hepatitis B.Additionally,liver tissue was regenerated and liver function was restored.Han-Min Li Zhi-Hua Ye Jun Zhang Xiang Gao Yan-Ming Chen Xin Yao Jian-Xun Gu Lei Zhan Yang Ji Jian-Liang Xu Ying-He Zeng Fan Yang Lin Xiao Guo-Guang Sheng Wei Xin Qi Long Qing-Jing Zhu Zhao-Hong Shi Lian-Guo Ruan Jia-Yao Yang Chang-Chun Li Hong-Bin Wu Sheng-Duo Chen Xin-La Luo 2014World Journal of Gastroenterology2014,20,48:20
10Novel insights for high mobility group box 1 proteinmediated cellular immune response in sepsis:A systemic review显示文摘BACKGROUND:High mobility group box 1 protein(HMGB1) is a highly conserved,ubiquitous protein in the nuclei and cytoplasm of nearly all cell types.HMGB1 is secreted into the extracellular milieu and acts as a proinflammatory cytokine.In this article we reviewed briefly the cellular immune response mediated by HMGB1 in inflammation and sepsis.METHODS:This systemic review is mainly based on our own work and other related reports.RESULTS:HMGB1 can actively affect the immune functions of many types of cells including T lymphocytes,regulatory T cells(Tregs),dendritic cells(DCs),macrophages,and natural killer cells(NK cells).Various cellular responses can be mediated by HMGB1 which binds to cell-surface receptors[e.g.,the receptor for advanced glycation end products(RAGE),Toll-like receptor(TLR)2,and TLR4].Anti-HMGB1 treatment,such as anti-HMGB1 polyclonal or monoclonal antibodies,inhibitors(e.g.,ethyl pyruvate) and antagonists(e.g.,A box),can protect against sepsis lethality and give a wider window for the treatment opportunity.CONCLUSION:HMGB1 is an attractive target for the development of new therapeutic strategies in the treatment of patients with septic complications.Li-feng Huang Yong-ming Yao Zhi-yong Sheng 2012World Journal of Emergency Medicine2012,3,3:19
11Septic encephalopathy: When cytokines interact with acetylcholine in the brain显示文摘Sepsis-associated encephalopathy(SAE) is a brain dysfunction that occurs secondary to infection in the bo characterized by alteration of consciousness, ranging from delirium to coma, seizure or focal neurological signs. S involves a number of mechanisms, including neuroinflammation, in which the interaction between cytokines a acetylcholine results in neuronal loss and alterations in cholinergic signaling. Moreover, the interaction also occurs the periphery, accelerating a type of immunosuppressive state. Although its diagnosis is not specific in biochemis and imaging tests, it could potentiate severe outcomes, including increased mortality, cognitive decline, progress immunosuppression, cholinergic anti-inflammatory deficiency, and even metabolic and hydroelectrolyte imbalan Therefore, the bilateral communication between SAE and the multiple peripheral organs and especially the immu system should be emphasized in sepsis management.Qing-Hong Zhang Zhi-Yong Sheng Yong-Ming Yao 2014Journal of Medical Colleges of PLA(China)2014,29,2:16
12Efficacy of combined therapy in patients with hepatitis B virus-related decompensated cirrhosis显示文摘AIM: To investigate the efficacy and safety of combined de novo lamivudine (LAM) and adefovir dipivoxil (ADV) therapy in hepatitis B virus (HBV)-related decompensated liver cirrhosis patients. METHODS: One hundred and forty patients with HBVrelated decompensated cirrhosis were recruited, 70 patients were treated with combined LAM and ADV de novo therapy, and the other 70 patients were treated with LAM alone as controls. The follow-up period was 144 wk. All patients with LAM resistance were shifted to ADV. RESULTS: The percentage of HBV-related decompensated cirrhosis patients with undetectable HBV DNA inde novo combination group was 51.6% (33/64), 84.2% (48/57), and 92.3% (49/53) by weeks 48, 96, and 144, respectively. In monotherapy group, HBV DNA negativity rate was 46.1% (30/65), 56.1% (32/57), and 39.2% (20/51) by weeks 48, 96 and 144, respectively. There was a significant difference between the two groups by weeks 96 and 144 (P = 0.012 and 0.001). The hepatitis B e antigen seroconversion rate was 28.1% (9/32), 40.0% (12/30), and 53.6% (15/28) in the combination group by weeks 48, 96 and 144, respectively, and 24.2% (8/33), 31.0% (9/29), and 37.0% (10/27) by weeks 48, 96 and 144, respectively, in monotherapy group. A total of 68.6% (44/64), 84.2% (48/57), and 92.5% (49/53) patients achieved alanine aminotransferase (ALT) normalization by weeks 48, 96 and 144, respectively in the combination group. In monotherpy group, the ALT normalization rate was 64.6% (42/65) by week 48, 73.7% (42/57) by week 96, and 80.4% (41/51) by week 144. No patients in the combination group exhibited detectable resistance for at least 144 wk. The cumulative resistance rate in monotherapy group at weeks 48, 96, and 144 was 20.0%, 36.8%, and 56.9%. Both combination group and monotherapy group demonstrated an improvement in Child-Turcotte Pugh and Model for End-Stage Liver Disease scores at weeks 48, 96, and 144. All patients tolerated both combination and monotherapy. The ceratinine levels and glomerular filtration rate remained normal in all patients during the follow-up period. CONCLUSION: In HBV-related decompensated liver cirrhosis patients, the combined de novo LAM and ADV therapy is more efficacious and safer compared to LAM alone.Guo-Cai Lv Jin-Mei Yao Yi-Da Yang Lin Zheng Ji-Fang Sheng Yu Chen Lan-Juan Li 2013World Journal of Gastroenterology2013,19,22:13
13Angiogenesis effect of Astragalus polysaccharide combined with endothelial progenitor cells therapy in diabetic male rat following experimental hind limb ischemia显示文摘Tu Sheng Shao Anwen Ren Lihong Chen Tin Yao Dingguo 2014Chinese Medical Journal2014,,11:13
14Plasma D(-)-lactate as a new marker for diagnosis of acute intestinal injury following ischemia-reperfusion显示文摘PlasmaD()lactateasanewmarkerfordiagnosisofacuteintestinalinjuryfolowingischemiareperfusionYAOYongMing1,YUYan1,WUYe2,LUL...YAO YongMing1, YU Yan1, WU Ye2, LU LianRong1 and SHENG ZhiYong1 1997World Journal of Gastroenterology1997,3,4:12
15Osteoarthritis:pathogenic signaling pathways and therapeutic targets显示文摘Osteoarthritis(OA)is a chronic degenerative joint disorder that leads to disability and affects more than 500 million population worldwide.OA was believed to be caused by the wearing and tearing of articular cartilage,but it is now more commonly referred to as a chronic whole-joint disorder that is initiated with biochemical and cellular alterations in the synovial joint tissues,which leads to the histological and structural changes of the joint and ends up with the whole tissue dysfunction.Currently,there is no cure for OA,partly due to a lack of comprehensive understanding of the pathological mechanism of the initiation and progression of the disease.Therefore,a better understanding of pathological signaling pathways and key molecules involved in OA pathogenesis is crucial for therapeutic target design and drug development.In this review,we first summarize the epidemiology of OA,including its prevalence,incidence and burdens,and OA risk factors.We then focus on the roles and regulation of the pathological signaling pathways,such as Wnt/β-catenin,NF-κB,focal adhesion,HIFs,TGFβ/ΒΜP and FGF signaling pathways,and key regulators AMPK,mTOR,and RUNX2 in the onset and development of OA.In addition,the roles of factors associated with OA,including MMPs,ADAMTS/ADAMs,and PRG4,are discussed in detail.Finally,we provide updates on the current clinical therapies and clinical trials of biological treatments and drugs for OA.Research advances in basic knowledge of articular cartilage biology and OA pathogenesis will have a significant impact and translational value in developing OA therapeutic strategies.Qing Yao Xiaohao Wu Chu Tao Weiyuan Gong Mingjue Chen Minghao Qu Yiming Zhong Tailin He Sheng Chen Guozhi Xiao 2023Signal Transduction and Targeted Therapy2023,8,3:11
16Comparison of immediate and followup results between transradial and transfemoral approach for percutaneous coronary intervention in true bifurcational lesions显示文摘在为在分叉的经皮的冠的干预(一种总线标准) 的 transradial 和 transfemoral 途径之间的功效和安全的背景 A 比较没被做。这研究评估了 transradial 一种总线标准(TRI ) 的可行性并且在 bifurcations.Methods 把立即、紧跟的结果与 transfemoral 一种总线标准(TFI ) 作比较有分叉的 134 个连续病人从 2004 年 4 月在我们的医院里与打印机控制语言被对待到 2005 年 10 月。这些,在 TFI 组在 TRI 组和 74 个病人(101 损害) 有 60 个病人(88 损害) 。分叉类型根据因斯蒂图特·卡迪奥瓦苏莱雷·帕里斯·苏德 Classification.Results TRI 组的意见被分类有的更小的 stent 直径((3.YANG Yue-jin XU Bo CHEN Ji-lin KANG Sheng QIAO Shu-bin QIN Xue-wen YAO Min CHEN Jue WU Yong-jian LIU Hai-bo YUAN Jin-qing YOU Shi-jie LI Jian-jun DAI Jun GAO Run-lin 2007Chinese Medical Journal2007,,7:11
17Characteristics of interior noise of a Chinese high-speed train under a variety of conditions显示文摘目的:研究高速列车在不同速度(260~385 km/h)、无砟和有砟轨道以及明线和隧道运行时的车内噪声特性,为高速列车车内减振降噪和车体低噪声设计提供科学依据。创新点:系统分析高速列车在不同运行条件下的车内噪声总值变化、空间分布、频谱特性和声源贡献,掌握车内噪声随列车运行速度的变化规律、轨道型式和隧道混响对车内噪声的影响,研究轮轨噪声、气动噪声和弓网噪声对车内噪声的作用。方法:1.根据不同的列车运行速度,分析车内噪声的变化规律;通过进一步对比头尾车运行时,不同测点位置的噪声总值、显著频率和声源贡献,研究气动作用对车内噪声的影响。2.针对不同轨道型式,分析车内噪声的差异特性;通过进一步对比不同速度下的前、后转向架上方车内噪声测点(其中一个还位于受电弓下方)的噪声总值、显著频率和声源贡献,研究有砟和无砟轨道、弓网噪声对车内噪声的影响以及速度因素的作用。3.对于隧道运行,分析不同速度下在明线和隧道运行时的车内噪声总值和显著频率,研究隧道混响对车内噪声的影响以及速度因素的作用。结论:1.TC01车无论作为头车或尾车运行,车内观光区的噪声均主要受气动作用影响。2.随着列车运行速度的提高,轨道型式的不同对车内噪声的影响有所降低。3.隧道混响对中间车的影响要高于头车。Jie ZHANG Xin-biao XIAO Xiao-zhen SHENG Rong FU Dan YAO Xue-song JIN 2017Journal of Zhejiang University-Science A(Applied Physics & Engineering)2017,18,8:10
18Comparison of drug eluting stents with bare metal stents in daily practice for bifurcation lesions in Chinese patients显示文摘背景最近,众多的使随机化并且控制的试用在经皮的冠的干预(一种总线标准) 以后关于狭窄的重要减小和症状的复发和临床的结果的改进表明了药 eluting stents (DES ) 的大优点。很少在中国人口为分叉 angioplasty 对在 DES 和赤裸的金属 stents (BMS ) 之间的比较效果被知道。我们从 2004 年 4 月为分叉 lesions.Methods 的治疗把在 DES 和 BMS 之间的住院病人和 7 月的后续结果比作 2005 年 10 月, 291 个中国病人[85.9% 男、吝啬的年龄(57.8 ????????? 剏??? € ?‥ 吗??KANG Sheng YANG Yue-jin XU Bo CHEN Ji-lin QIAO Shu-bin YAO Min CHEN Jue WU Yong-jian LIU Hai-bo DAI Jun YUAN Jin-qing LI Jian-jun GAO Run-lin 2006Chinese Medical Journal2006,,14:10
19Drift and deposition of pesticide applied by UAV on pineapple plants under different meteorological conditions显示文摘Spray drift has always been a focus research area in the field of unmanned aerial vehicle(UAV)application.Under the fixed premises of UAV operating parameters,such as height,speed and spraying liquid,the droplet drift is mainly affected by meteorological conditions.In this research,the spray drift and deposition tests were conducted using a QuanFeng120 UAV in a pineapple field under various different meteorological conditions.The experimental results showed that with the changes of UAV operating height and wind speed,the start position of the in-swath deposition area changed 4 m in the extreme situation.The percentage of the total spray drift was from 15.42%to 55.76%.The position of cumulative spray drift that accounted for 90%of the total spray drift was from 3.70 m to 46.50 m relative to the flight line.According to the downwind spray drift curve,the nonlinear equations of the same type under the four operating conditions of the UAV were fitted.The spray drift and the deposition of UAV application were significantly affected by different meteorological conditions and UAV operating heights.The results could provide a theoretical basis for UAV spraying in pineapple plants and support for spray drift control and prediction.Juan Wang Yubin Lan Huihui Zhang Yali Zhang Sheng Wen Weixiang Yao Jiajian Deng 2018International Journal of Agricultural and Biological Engineering2018,11,6:10
20First proof-of-principle experiment with the post-accelerated isotope separator on-line beam at BRIF:measurement of the angular distribution of ^(23)Na+^(40)Ca elastic scattering显示文摘The reaction dynamics of exotic nuclei near the drip line is one of the main research topics of current interest.Elastic scattering is a useful probe for investigating the size and surface diffuseness of exotic nuclei.The development of rare isotope accelerators offers opportunities for such studies.To date,many relevant measurements have been performed at accelerators using the projectile fragmentation technique,while the measurements at accelerators using isotope separator on-line(ISOL)systems are still quite scarce.In this work,we present the first proof-of-principle experiment with a post-accelerated ISOL beam at the Beijing Radioactive Ion Beam Facility(BRIF)by measuring the angular distribution of elastic scattering for the stable nucleus^(23)Na from the doubly magic nucleus^(40)Ca at energies above the Coulomb barrier.The angular distribution measured by a silicon strip detector array in a scattering chamber using the ISOL beam at BRIF is in good agreement with that measured by the high-precision Q3 D magnetic spectrograph using the nonISOL beam at nearly the same energy.This work provides useful background for making BRIF a powerful tool for the investigation of the reaction dynamics of exotic nuclei.Wei Nan Bing Guo Cheng-Jian Lin Lei Yang Dong-Xi Wang Yang-Ping Shen Bing Tang Bao-Qun Cui Tao Ge Yin-Long Lyu Hui-Ming Jia Yun-Ju Li Chen Chen Li-Hua Chen Qi-Wen Fan Xin-Yue Li Gang Lian Jian-Cheng Liu Tian-Peng Luo Nan-Ru Ma Rui-Gang Ma Xie Ma Ying-Jun Ma Wei-Ke Nan Dan-Yang Pang You-Bao Wang Pei-Wei Wen Feng Yang Yong-Jin Yao Sheng Zeng Hao Zhang Fu-Peng Zhong Shan-Hao Zhong Zhi-Hong Li Tian-Jue Zhang Wei-Ping Liu BRIF Collaboration 2021Nuclear Science and Techniques2021,32,5:9
返回顶部 每页显示:
共26页 首页 上一页 第1页 下一页 末页 /26 跳转

网站首页 | 关于我们 | 联系我们 | 产品服务 | 客服中心 | 广告服务 | 版权声明 | 网站联盟 | 友情链接 | 售卡网点

版权所有© 渝B2-20050021-1 渝公网安备 50019002500403号 违法和不良信息举报中心

互联网出版许可证 新出网证(渝)字10号 全国400电话 - 免长途话费